Adma Biologics (ADMA) Change in Account Payables (2011 - 2025)

Adma Biologics has reported Change in Account Payables for 13 years, with the latest figure at -$2.2 million in Q4 2025.

• For the quarter ending Q4 2025, Change in Account Payables fell 155.89% year-over-year to -$2.2 million; the trailing twelve-month figure through Dec 2025 stood at $2.3 million (down 43.86% YoY), and the FY2025 full-year result was $2.3 million, down 43.86% from the prior year.
• Change in Account Payables for Q4 2025 stood at -$2.2 million, up from -$4.9 million in the prior quarter.
• The five-year high for Change in Account Payables was $13.8 million in Q3 2022, with the low at -$12.0 million in Q4 2022.
• Historically, Change in Account Payables has averaged $623750.0 across 5 years, with a median of $66000.0 in 2023.
• Annual changes were most pronounced in 2024 — Change in Account Payables surged 16280.0% — and 2025, when it slumped 401.36%.
• Adma Biologics' Change in Account Payables stood at -$4.9 million in 2021, then tumbled by 146.61% to -$12.0 million in 2022, then surged by 141.73% to $5.0 million in 2023, then fell by 21.07% to $3.9 million in 2024, then sank by 155.89% to -$2.2 million in 2025.
• The last three Change in Account Payables figures came in at -$2.2 million (Q4 2025), -$4.9 million (Q3 2025), and $9.3 million (Q2 2025), per Business Quant data.